Journal Article10.1002/ADHM.201200338
Optically traceable solid lipid nanoparticles loaded with siRNA and paclitaxel for synergistic chemotherapy with in situ imaging
106
TL;DR: It is suggested that LDL‐mimetic SLNs can be utilized as a multifunctional and optically traceable nanocarrier for efficient anticancer theranostics and show synergistic therapeutic effects of paclitaxel‐siRNA combination.
read more
Abstract: Here, we report quantum dot-incorporating solid lipid nanoparticles (SLNs) for anticancer theranostics with synergistic therapeutic effects of paclitaxel-siRNA combination. The natural components of a low-density lipoprotein (LDL) are reconstituted to produce LDL-mimetic SLNs having a stable core/shell nanostructure incorporating quantum dots and paclitaxel within the lipid shell while anionic siRNA molecules are electrostatically complexed with the outer surface of SLNs. The produced SLN/siRNA complexes efficiently deliver both of paclitaxel and Bcl-2 targeted siRNA into human lung carcinoma cells and exhibit synergistic anticancer activities by triggering caspase-mediated apoptosis as determined by median effect plot analysis. Moreover, the strong fluorescence from quantum dots within SLNs enables in situ visualization of intracellular translocation of SLNs into cancer cells. Our study suggests that LDL-mimetic SLNs can be utilized as a multifunctional and optically traceable nanocarrier for efficient anticancer theranostics.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Nanotechnology for Multimodal Synergistic Cancer Therapy
TL;DR: In this review, state-of-the-art studies concerning recent advances in nanotechnology-mediated multimodal synergistic therapy will be systematically discussed, with an emphasis on the construction of multifunctional nanomaterials for realizing bimodal and trimodal synergy therapy.
1.5K
Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases.
Meenu Mehta,Deeksha,Devesh Tewari,Gaurav Gupta,Rajendra Awasthi,Harjeet Singh,Parijat Pandey,Dinesh Kumar Chellappan,Ridhima Wadhwa,Trudi Collet,Philip M. Hansbro,S. Rajesh Kumar,Lakshmi Thangavelu,Poonam Negi,Kamal Dua,Kamal Dua,Kamal Dua,Saurabh Satija +17 more
TL;DR: Various novel dosage forms like nanoparticles, liposomes that can be used efficiently for the delivery of various oligonucleotides such as siRNA and miRNA are focused on.
613
Nanotheranostics ˗ Application and Further Development of Nanomedicine Strategies for Advanced Theranostics
TL;DR: This review summarizes the various nanocarriers developed so far in the literature for nanotheranostics, which include polymer conjugations, dendrimers, micelles, liposomes, metal and inorganic nanoparticles, carbon nanotubes, and nanoparticles of biodegradable polymers for sustained, controlled and targeted co-delivery of diagnostic and therapeutic agents for better theranostic effects with fewer side effects.
Lipid-Based Nanocarriers for RNA Delivery
TL;DR: Focus of the discussion is on the various challenges researchers face when developing lipid-based RNA nanocarriers, such as the toxicity of cationic lipids and issues related to PEGylated lipids, as well as the strategies employed in tackling these challenges.
Nanoparticle-based drug delivery for therapy of lung cancer: progress and challenges
TL;DR: This review summarizes current progress and challenges in nanoparticle-based drug delivery systems, citing recent examples targeted at lung cancer treatment.
References
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
Ting-Chao Chou,Paul Talalay +1 more
TL;DR: A generalized method for analyzing the effects of multiple drugs and for determining summation, synergism and antagonism has been proposed and has been used to analyze experimental data obtained from enzymatic, cellular and animal systems.
7.4K
The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis
TL;DR: In a cell-free apoptosis system, mitochondria spontaneously released cytochrome c, which activated DEVD-specific caspases, leading to fodrin cleavage and apoptotic nuclear morphology, and Bcl-2 acts to inhibit cy tochrome c translocation, thereby blocking caspase activation and the apoptotic process.
4.9K
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
TL;DR: Relevant issues for the introduction of SLN to the pharmaceutical market, such as status of excipients, toxicity/tolerability aspects and sterilization and long-term stability including industrial large scale production are discussed.
3.7K
Effect of pegylation on pharmaceuticals
J. Milton Harris,Robert B. Chess +1 more
TL;DR: How PEGylation can result in drugs that are often more effective and safer, and which show improved patient convenience and compliance are reviewed.
3.5K
Solid lipid nanoparticles: Production, characterization and applications
W. Mehnert,Karsten Mäder +1 more
TL;DR: An overview about the selection of the ingredients, different ways of SLN production and SLN applications, and the in vivo fate of the carrier are presented.
3.2K